J Rheumatol 2022 Apr 15. Epub 2022 Apr 15.
This study was funded in part by a grant from the Vasculitis Foundation awarded to LL. L. Lally, MD, R.F. Spiera, MD, Department of Rheumatology, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medicine, New York, New York, USA; N. Narula, MD, Department of Pathology, NYU Langone, New York, New York, USA; N. Goodfellow, MD, R. Luqmani, DM, FRCP, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; D. Pisapia, MD, Department of Pathology, Weill Cornell Medicine, New York, New York, USA. The authors declare no conflicts of interest to declare relevant to this article. Address correspondence to Dr. L. Lally, Department of Rheumatology, Hospital for Special Surgery, Department of Medicine, Weill Cornell Medicine, 535 E. 70th Street, New York, NY 10021, USA. Email: Accepted for publication April 6, 2022.
Objective: Aberrant Rho-associated protein kinase (ROCK) activity is implicated in several vascular and immunologic disorders. We previously demonstrated increased ROCK activity in histopathologically negative temporal artery biopsies (TABs) in subjects with clinical giant cell arteritis (GCA) compared to those without GCA. This current study aimed to examine ROCK activity in a larger cohort of biopsy-negative GCA subjects and to validate the prior findings. Read More